SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-200833"
 

Search: onr:"swepub:oai:DiVA.org:umu-200833" > The 2022 updated Eu...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Bedke, JensDepartment of Urology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany (author)

The 2022 updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • Elsevier,2023
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-200833
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-200833URI
  • https://doi.org/10.1016/j.eururo.2022.10.010DOI
  • https://lup.lub.lu.se/record/86c3e519-efeb-4471-b309-8359e033d33dURI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse. In 2021, the European Association of Urology RCC Guidelines Panel issued a weak recommendation for adjuvant pembrolizumab for high-risk ccRCC as defined by the trial until final overall survival data and results from other trials were available. Meanwhile, the primary DFS endpoints were not met for adjuvant atezolizumab (PD-L1 inhibitor; IMmotion010), adjuvant nivolumab plus ipilimumab (CheckMate 914), or perioperative nivolumab (PROSPER). Owing to heterogeneity, a meta-analysis is not recommended. Pembrolizumab remains the only immune checkpoint inhibitor currently recommended in this setting. Overall survival data are immature and biomarkers to predict outcome are lacking. Uncertainty exists and overtreatment is occurring. Treatment decisions should be made with caution and with the involvement of each patient.Patient summary: New results from three trials of immunotherapy after surgery for kidney cancer to reduce the risk of recurrence showed no improvement with these treatments. These results are in contrast to an earlier study that showed that the antibody pembrolizumab did extend the time before kidney cancer recurrence, even though it is not yet clear if overall survival is longer. Thus, we cautiously recommend pembrolizumab as additional treatment in high-risk kidney cancer after surgery, but patient preference should be carefully considered and the risk of overtreatment should be discussed.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Albiges, LaurenceDepartment of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France,Institut Gustave Roussy (author)
  • Capitanio, UmbertoDepartment of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy (author)
  • Giles, Rachel H.International Kidney Cancer Coalition, Duivendrecht, Netherlands (author)
  • Hora, MilanDepartment of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Czech Republic (author)
  • Ljungberg, Börje,Professor,1949-Umeå University,Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001 (author)
  • Marconi, LorenzoDepartment of Urology, Coimbra University Hospital, Coimbra, Portugal (author)
  • Klatte, TobiasDepartment of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany,Charité - University Medicine Berlin (author)
  • Volpe, AlessandroDepartment of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy (author)
  • Abu-Ghanem, YasminDepartment of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel (author)
  • Dabestani, SaeedLund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,Urologi,Urological cancer, Malmö,Lund University Research Groups,Urology(Swepub:lu)med-sdd (author)
  • Fernández-Pello, SergioDepartment of Urology, Cabueñes University Hospital, Gijón, Spain (author)
  • Hofmann, FabianUmeå University (author)
  • Kuusk, TeeleDepartment of Urology, Homerton University Hospital, London, United Kingdom,Homerton University Hospital NHS Foundation Trust (author)
  • Tahbaz, RanaDepartment of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany,Charité - University Medicine Berlin (author)
  • Powles, ThomasThe Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, United Kingdom (author)
  • Bex, AxelThe Royal Free London NHS Foundation Trust, London, United Kingdom; UCL Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands (author)
  • Department of Urology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, GermanyDepartment of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France (creator_code:org_t)

Related titles

  • In:European Urology: Elsevier83:1, s. 10-140302-28381873-7560

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view